Despite loud objections from its advisers, the FDA granted an accelerated approval to AstraZeneca's ovarian cancer treatment, clearing an oral therapy the U.K. drugmaker believes will bring in blockbuster sales.
Gilead Sciences is pushing further into oncology R&D, teaming up with Ono Pharmaceutical on a cancer treatment that could complement its first major success in the field.
Eli Lilly is buying back into Adocia's pitch for a fast-acting insulin, reversing an earlier decision and signing a collaboration deal worth up to $570 million.
Lundbeck is giving up on its efforts to develop desmoteplase as a treatment for stroke, as disappointing data have made it unclear just how to proceed.
Auspex Pharmaceuticals' treatment for a movement disorder tied to Huntington's disease met its main goal in a late-stage study, the company said, clearing the way for a 2015 FDA filing.
Cyclacel Pharmaceuticals' in-development leukemia drug has little chance of meeting its primary goal in a late-stage study, independent advisers said. But, because the treatment isn't leading to serious side effects, the company is keeping the trial running.
Taking an early look at data from an ongoing study of Sophiris' lead drug, independent advisers say the prostate-shrinking therapy didn't meet its predefined threshold for efficacy, casting a shadow over the biotech's only clinical asset.
Moving on from the slow demise of its Merck KGaA-partnered cancer vaccine, Seattle's Oncothyreon has bought out co-developer Array BioPharma, acquiring exclusive rights to the pair's early-stage breast cancer candidate.
Novartis' new anti-inflammatory treatment cleared up psoriasis better than Johnson & Johnson's Stelara in a Phase III trial, a second head-to-head victory for the injectable drug as it nears U.S. and European approvals.
Houston's Bellicum Pharmaceuticals has laid out plans to raise as much as $121 million in an IPO, cash that'll support its proprietary take on a promising new approach to oncology.